In 2018, Reig Jofre, a pharmaceutical company listed on the continuous market of the Spanish stock exchange, set up the Syna Therapeutics joint-venture, 50% owned by LeanBio and REIG JOFRE, for the development of biopharmaceutical products in the field of biosimilars and innovative molecules. After 4 years, Syna Therapeutics has just signed an exclusive license agreement with Intas Pharmaceuticals Ltd. (“Intas”) and its subsidiary Accord Healthcare for the worldwide marketing of its LB-0702 biosimilar medicine.
Under the terms of the agreement, Syna Therapeutics In 2023, it will begin clinical trials of its biosimilar LB-07802 to treat pathologies in the field of hematology. For its part, Intas Pharmaceutical Ltd., a global biopharmaceutical company, will cover the marketing costs. Intas currently has one of the largest sales, marketing and distribution networks for biosimilars in the world, particularly to hospitals, with a presence in 85 countries.
REIG JOFRE will contribute to the development and stabilization of the finished pharmaceutical product, in addition to offering its first-rate global production capacity at its new development and specialized production center in Barcelona, which, after an investment of 40 million euros completed in 2021, has with state-of-the-art technology and the highest quality standards for sterile injectables and lyophilized biopharmaceutical products, with an annual capacity of up to 45 million lyophilized aseptic vials and 50 million liquid solution vials.
REIG JOFRE thus contributes to a greater integration of the biological drug development and manufacturing process, uniting through Syna Therapeutics the development of the active ingredient and the production of the final biopharmaceutical product.
Patient access to innovative treatments worldwide
A biosimilar (or similar biological medicine) is a biological medicine equivalent in quality, efficacy and safety to an original biological medicine, called a reference product. Biosimilars are characterized by being large molecules with greater structural complexity than chemically synthesized drugs, which makes them very sensitive to changes in the manufacturing process.
In recent decades, biotechnological drugs have played an increasingly relevant role in health care and treatment. In this sense, and despite the complexity of the technology required for the development of off-patent biologicals and the costly manufacturing processes, it is expected that in the coming years the development of biosimilars will be a significant area of growth to deliver products biotech drugs more effectively to patients around the world, either by being able to offer more sustainable prices in the markets where the original biologic exists, or by being able to give access to innovative treatments to all those world markets in which the therapy not available.
REIG JOFRE, dedicated to the research, development, manufacture and marketing of pharmaceutical products and food supplements, structures its product development activity in three business units: Pharmaceutical Technologies specialized in sterile and lyophilized injectable drugs, and beta-lactam antibiotics; Specialty Pharmacare in dermatology and osteoarticular, mainly; Y Consumer Healthcare with food supplements aimed at consumers under the Forté Pharma brand, mainly in France, Belgium, Spain and Portugal, and other OTC products. Founded in 1929 in Barcelona (Spain), REIG JOFRE has more than 1,100 employees, 4 development and production centers in Europe, subsidiaries in 8 countries (Spain, France, Portugal, Belgium, Sweden, United Kingdom, Poland and Singapore) and 155 business partners in more than 70 countries. In 2021, the company’s turnover reached 236 million euros.